Skip to main content

Table 1 Clinical, demographic, serological, and therapeutic characteristics of patients with RA and HC

From: TNFα expressed on the surface of microparticles modulates endothelial cell fate in rheumatoid arthritis

  Patients with RA (n = 20) HC (n = 20)
Demographic parameters
 Female/male 19/1 20/0
 Age, years (median (IQR)) 58.5 (50–67) 58 (50–65)
 Disease duration, years (mean ± SD), 5.3 ± 5.6  
Disease activity
 DAS28 (mean ± SD) 4.1 ± 1.7  
 TJ, n (mean ± SD) 6.16 ± 5.9  
 SJ, n (mean ± SD) 2.79 ± 2.7  
 CDAI (mean ± SD) 18.8 ± 10.7  
 HAQ (mean ± SD) 1.15 ± 0.8  
Laboratory parameters N (%)  
 RF+ 15 (75)  
 ACPA+ 15(75)  
 ESR, mm/h (mean ± SD) 16.5 ± 10.3  
 CRP, mg/dl (mean ± SD) 0.7 ± 0.73  
Therapy
 Concurrent csDMARDs (n (%)) 20 (100)  
 ETA (n (%)) 20 (100)  
  1. RA rheumatoid arthritis, HC healthy controls, SD standard deviation, DAS28 Disease Activity Score in 28 joints, TJ tender joints, SJ swollen joints, CDAI Clinical Disease Activity Index, HAQ Health Assessment Questionnaire, RF rheumatoid factor, ACPA anti-citrullinated peptide antibodies, ESR erythrocyte sedimentation rate, CRP C-reactive protein, csDMARDs conventional synthetic disease-modifying antirheumatic drugs